Find Pegloticase manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set

Drugs in Development

read-more
read-more

Details:

sBLA Submission based on recent results from the MIRROR randomized clinical trial, which showed a 71% response rate for patients randomized to receive KRYSTEXXA (Pegloticase) PEGylated uric acid specific enzyme, plus methotrexate for people living with uncontrolled Gout.


Lead Product(s): Pegloticase,Methotrexate

Therapeutic Area: Rheumatology Brand Name: Krystexxa

Study Phase: Phase IVProduct Type: Enzyme

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 01, 2022

blank

01

STLE Annual Meeting
Not Confirmed
STLE Annual Meeting
Not Confirmed

Details : sBLA Submission based on recent results from the MIRROR randomized clinical trial, which showed a 71% response rate for patients randomized to receive KRYSTEXXA (Pegloticase) PEGylated uric acid specific enzyme, plus methotrexate for people living with u...

Product Name : Krystexxa

Product Type : Enzyme

Upfront Cash : Inapplicable

October 01, 2022

blank

Details:

The co-administration of KRYSTEXXA (pegloticase) with an immunomodulator like methotrexate has increasingly been employed in patients with uncontrolled gout to help reduce the development of antidrug antibodies, which can affect treatment efficacy with biologics.


Lead Product(s): Pegloticase,Methotrexate

Therapeutic Area: Rheumatology Brand Name: Krystexxa

Study Phase: Phase IVProduct Type: Enzyme

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 11, 2022

blank

02

STLE Annual Meeting
Not Confirmed
STLE Annual Meeting
Not Confirmed

Details : The co-administration of KRYSTEXXA (pegloticase) with an immunomodulator like methotrexate has increasingly been employed in patients with uncontrolled gout to help reduce the development of antidrug antibodies, which can affect treatment efficacy with b...

Product Name : Krystexxa

Product Type : Enzyme

Upfront Cash : Inapplicable

August 11, 2022

blank

Details:

Application based on recent MIRROR randomized controlled trial results, which showed 71% of patients randomized to receive KRYSTEXXA (pegloticase), a PEGylated uric acid specific enzyme plus methotrexate achieved a complete response.


Lead Product(s): Pegloticase,Methotrexate

Therapeutic Area: Rheumatology Brand Name: Krystexxa

Study Phase: Phase IVProduct Type: Enzyme

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 03, 2022

blank

03

STLE Annual Meeting
Not Confirmed
STLE Annual Meeting
Not Confirmed

Details : Application based on recent MIRROR randomized controlled trial results, which showed 71% of patients randomized to receive KRYSTEXXA (pegloticase), a PEGylated uric acid specific enzyme plus methotrexate achieved a complete response.

Product Name : Krystexxa

Product Type : Enzyme

Upfront Cash : Inapplicable

July 03, 2022

blank

Details:

KRYSTEXXA® (pegloticase injection) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.


Lead Product(s): Pegloticase,Methotrexate

Therapeutic Area: Rheumatology Brand Name: Krystexxa

Study Phase: Phase IVProduct Type: Enzyme

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 24, 2022

blank

04

STLE Annual Meeting
Not Confirmed
STLE Annual Meeting
Not Confirmed

Details : KRYSTEXXA® (pegloticase injection) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.

Product Name : Krystexxa

Product Type : Enzyme

Upfront Cash : Inapplicable

May 24, 2022

blank

Details:

The MIRROR randomized controlled trial outcomes provided a clear view of improvements in patient response and reductions in infusion reactions for KRYSTEXXA plus low-dose (15 mg/week) methotrexate compared to KRYSTEXXA plus placebo.


Lead Product(s): Pegloticase,Methotrexate

Therapeutic Area: Rheumatology Brand Name: Krystexxa

Study Phase: Phase IVProduct Type: Enzyme

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 06, 2022

blank

05

STLE Annual Meeting
Not Confirmed
STLE Annual Meeting
Not Confirmed

Details : The MIRROR randomized controlled trial outcomes provided a clear view of improvements in patient response and reductions in infusion reactions for KRYSTEXXA plus low-dose (15 mg/week) methotrexate compared to KRYSTEXXA plus placebo.

Product Name : Krystexxa

Product Type : Enzyme

Upfront Cash : Inapplicable

January 06, 2022

blank

Details:

The Company announced two new KRYSTEXXA development programs: KRYSTEXXA, with methotrexate monthly dosing trial and a KRYSTEXXA retreatment trial evaluating KRYSTEXXA, with methotrexate, in patients who have previously failed KRYSTEXXA.


Lead Product(s): Pegloticase,Methotrexate

Therapeutic Area: Rheumatology Brand Name: Krystexxa

Study Phase: Phase IVProduct Type: Enzyme

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 01, 2021

blank

06

STLE Annual Meeting
Not Confirmed
STLE Annual Meeting
Not Confirmed

Details : The Company announced two new KRYSTEXXA development programs: KRYSTEXXA, with methotrexate monthly dosing trial and a KRYSTEXXA retreatment trial evaluating KRYSTEXXA, with methotrexate, in patients who have previously failed KRYSTEXXA.

Product Name : Krystexxa

Product Type : Enzyme

Upfront Cash : Inapplicable

November 01, 2021

blank

Details:

Results show that 71% (71 of 100) of patients who were randomized to receive KRYSTEXXA with methotrexate compared to 40% (21 of 52) of patients who were randomized to receive KRYSTEXXA with placebo achieved the primary endpoint (p<0.001).


Lead Product(s): Pegloticase,Methotrexate

Therapeutic Area: Rheumatology Brand Name: Krystexxa

Study Phase: Phase IVProduct Type: Enzyme

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 25, 2021

blank

07

STLE Annual Meeting
Not Confirmed
STLE Annual Meeting
Not Confirmed

Details : Results show that 71% (71 of 100) of patients who were randomized to receive KRYSTEXXA with methotrexate compared to 40% (21 of 52) of patients who were randomized to receive KRYSTEXXA with placebo achieved the primary endpoint (p<0.001).

Product Name : Krystexxa

Product Type : Enzyme

Upfront Cash : Inapplicable

October 25, 2021

blank

Details:

The Reducing Immunogenicity of Pegloticase trial showed that 86% of patients receiving co-therapy of KRYSTEXXA with the immunomodulator mycophenolate mofetil achieved serum uric acid (sUA) ≤ 6 mg/dL at 12 weeks vs 40% of patients (4 of 10) receiving KRYSTEXXA monotherapy.


Lead Product(s): Pegloticase,Mycophenolate Mofetil

Therapeutic Area: Rheumatology Brand Name: Krystexxa

Study Phase: Phase IVProduct Type: Enzyme

Sponsor: University of Michigan

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 04, 2021

blank

08

STLE Annual Meeting
Not Confirmed
STLE Annual Meeting
Not Confirmed

Details : The Reducing Immunogenicity of Pegloticase trial showed that 86% of patients receiving co-therapy of KRYSTEXXA with the immunomodulator mycophenolate mofetil achieved serum uric acid (sUA) ≤ 6 mg/dL at 12 weeks vs 40% of patients (4 of 10) receiving KR...

Product Name : Krystexxa

Product Type : Enzyme

Upfront Cash : Inapplicable

July 04, 2021

blank

Details:

PKTX-001 has shown to significantly improve cell survival and integration into host tissue and will be a valuable asset in the field of regenerative medicine in the future.


Lead Product(s): Pegloticase

Therapeutic Area: Ophthalmology Brand Name: PKTX-001

Study Phase: PreclinicalProduct Type: Enzyme

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 04, 2021

blank

09

ProtoKinetix

U.S.A
arrow
STLE Annual Meeting
Not Confirmed

ProtoKinetix

U.S.A
arrow
STLE Annual Meeting
Not Confirmed

Details : PKTX-001 has shown to significantly improve cell survival and integration into host tissue and will be a valuable asset in the field of regenerative medicine in the future.

Product Name : PKTX-001

Product Type : Enzyme

Upfront Cash : Inapplicable

July 04, 2021

blank

Details:

PROTECT trial evaluating the use of KRYSTEXXA (pegloticase injection) in people with chronic gout refractory to conventional therapies who have received a kidney transplant, as well as pharmacokinetic data regarding the concomitant use of KRYSTEXXA and methotrexate.


Lead Product(s): Pegloticase

Therapeutic Area: Rheumatology Brand Name: Krystexxa

Study Phase: Approved FDFProduct Type: Enzyme

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 21, 2021

blank

10

STLE Annual Meeting
Not Confirmed
STLE Annual Meeting
Not Confirmed

Details : PROTECT trial evaluating the use of KRYSTEXXA (pegloticase injection) in people with chronic gout refractory to conventional therapies who have received a kidney transplant, as well as pharmacokinetic data regarding the concomitant use of KRYSTEXXA and m...

Product Name : Krystexxa

Product Type : Enzyme

Upfront Cash : Inapplicable

May 21, 2021

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

China Battery Fair
Not Confirmed
arrow
arrow
China Battery Fair
Not Confirmed

PEGLOTICASE

Brand Name : KRYSTEXXA

Dosage Form : INJECTABLE; INJECTION

Dosage Strength : 8MG

Packaging :

Approval Date :

Application Number : 125293

Regulatory Info :

Registration Country : USA

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

read-more
read-more

01

Brand Name : Krystexxa

Pegloticase

arrow
China Battery Fair
Not Confirmed

Brand Name : Krystexxa

U.S.A
arrow
China Battery Fair
Not Confirmed

Pegloticase

Main Therapeutic Indication : Rheumatology

Currency : USD

2023 Revenue in Millions : 272

2022 Revenue in Millions : 0

Growth (%) : Acquired from Horizon

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty